Similar to the single treatment with AZD8186, the PI3Kα specific inhibitor BYL-719 led to an initial decrease in the phosphorylation of AKT in the AZD8186-resistant DLBCL cell lines WSUDLCL2, and U2932 (Fig. 4b). This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.